- Home
- BKU vs NAMS Comparison
BKU vs NAMS Comparison
Compare BKU & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKU
- NAMS
- Stock Information
- Founded
- BKU 2009
- NAMS 2019
- Country
- BKU United States
- NAMS Netherlands
- Employees
- BKU N/A
- NAMS N/A
- Industry
- BKU Savings Institutions
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- BKU Finance
- NAMS Health Care
- Exchange
- BKU Nasdaq
- NAMS Nasdaq
- Market Cap
- BKU 2.9B
- NAMS 3.1B
- IPO Year
- BKU 2011
- NAMS N/A
- Fundamental
- Price
- BKU $39.70
- NAMS $32.22
- Analyst Decision
- BKU Hold
- NAMS Strong Buy
- Analyst Count
- BKU 11
- NAMS 9
- Target Price
- BKU $41.82
- NAMS $41.89
- AVG Volume (30 Days)
- BKU 911.1K
- NAMS 987.3K
- Earning Date
- BKU 10-22-2025
- NAMS 11-05-2025
- Dividend Yield
- BKU 3.12%
- NAMS N/A
- EPS Growth
- BKU 51.05
- NAMS N/A
- EPS
- BKU 3.41
- NAMS N/A
- Revenue
- BKU $999,760,000.00
- NAMS $64,006,000.00
- Revenue This Year
- BKU $15.41
- NAMS N/A
- Revenue Next Year
- BKU $6.24
- NAMS $1.67
- P/E Ratio
- BKU $11.65
- NAMS N/A
- Revenue Growth
- BKU 13.39
- NAMS 762.15
- 52 Week Low
- BKU $28.21
- NAMS $14.06
- 52 Week High
- BKU $44.45
- NAMS $34.62
- Technical
- Relative Strength Index (RSI)
- BKU 60.71
- NAMS 73.32
- Support Level
- BKU $37.36
- NAMS $27.15
- Resistance Level
- BKU $40.40
- NAMS $34.59
- Average True Range (ATR)
- BKU 0.99
- NAMS 1.56
- MACD
- BKU 0.04
- NAMS 0.54
- Stochastic Oscillator
- BKU 71.17
- NAMS 77.28
About BKU BankUnited Inc.
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.